A retrospective survey of the last 3 months of life in patients carrying glioblastoma: Clinical treatments and profiles

  • Authors:
    • Romain Rivoirard
    • Alexis Vallard
    • Claire Boutet
    • Alexander Tuan Falk
    • Clemence Garin
    • Anissa Adjabi
    • Delphine Hoarau
    • Fabien Forest
    • Marie‑Jeannette Fotso
    • Chloe Rancoule
    • Nicolas Magné
  • View Affiliations

  • Published online on: November 2, 2017     https://doi.org/10.3892/mco.2017.1479
  • Pages: 115-120
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioblastoma is one of the most common types of primary brain tumor. In situations of local recurrence, physicians can suggest either specific palliative anticancer treatments (SPAT; surgery, chemotherapy, radiotherapy) or best supportive care (BSC). The objective of the present study was to identify clinical factors that may have influenced the continuation or cessation of SPAT during the final 3 months of life in patients with glioblastoma. In the present retrospective single‑center study, all records of patients treated for glioblastoma, who succumbed to the disease between June 2006 and February 2014, were assessed. All selected patients were divided into two groups, according to treatments received during the last 3 months of life: The SPAT and BSC groups. A total of 148 patients were included: 81 patients in the SPAT group (group A) and 67 patients in the BSC group (group B). A performance status equal to 0 was observed for 17.3% of patients in group A vs. 6% in group B. Following progression, chemotherapy was administered in 39.5% of cases in group A vs. 20.9% of cases in group B (P=0.0149). The mean number of lines of chemotherapy administered in group A was equal to 1.44±0.77 as compared with 1.06±0.67 in group B (P=0.0017). SPAT are utilized frequently among patients approaching mortality due to a glioblastoma. Certain factors, including the utilization of novel chemotherapy after the first progression or number of lines of chemotherapy previously administered, may have influenced physicians' decisions whether to continue with the SPAT or not.

References

1 

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS: CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the united states in 2008–2012. Neuro Oncol. 17 Suppl 4:iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, Bauchet F, Kerr C, Fabbro M, Figarella-Branger D, et al: French brain tumor database: General results on 40,000 cases, main current applications and future prospects. Neurochirurgie. 58:4–13. 2012.(In French). View Article : Google Scholar : PubMed/NCBI

3 

Baldi I, Huchet A, Bauchet L and Loiseau H: Epidemiology of glioblastoma. Neurochirurgie. 56:433–440. 2010.(In French). View Article : Google Scholar : PubMed/NCBI

4 

Chakrabarti I, Cockburn M, Cozen W, Wang YP and Preston-Martin S: A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer. 104:2798–2806. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI

6 

Hart MG, Grant R, Garside R, Rogers G, Somerville M and Stein K: Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 16:CD0072942011.

7 

Lonjon N, Bauchet L, Duffau H, Fabbro-Peray P, Segnarbieux F, Paquis P and Lonjon M: Second surgery for glioblastoma. A 4-year retrospective study conducted in both the Montpellier and Nice Departments of Neurosurgery. A literature review. Neurochirurgie. 56:36–42. 2010.

8 

Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, et al: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. J Neurooncol. 102:417–424. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH and Wilson CB: Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg. 63:218–223. 1985. View Article : Google Scholar : PubMed/NCBI

10 

Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL and Elfring GL: Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 97(9 Suppl): S2381–S2386. 2003. View Article : Google Scholar

11 

Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, et al: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A north american brain tumor consortium study. Neuro-Oncol. 8:189–193. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, et al: Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 27:1262–1267. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Combs SE, Thilmann C, Edler L, Debus J and Schulz-Ertner D: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J Clin Oncol. 23:8863–8869. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, et al: Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas. J Clin Oncol. 28:3048–3053. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B and Ryu S: Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J Neurooncol. 92:185–191. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Derouesne C, Poitreneau J, Hugonot L, Kalafat M, Dubois B and Laurent B: Mini-Mental State Examination: A useful method for the evaluation of the cognitive status of patients by the clinician. Presse Med. 28:1141–1148. 1999.PubMed/NCBI

19 

Viel E, Chaigneau L, Fanton E, Kalbacher E, Thiery-Vuillemnin A, Villanueva C, Dobi E, Curtit E, Almotlak H, Aubry R and Pivot X: Specific anticancer treatments in the last 3 months of life: A French experience. Support Care Cancer. 21:405–412. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD and Weeks JC: Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 22:315–321. 2004. View Article : Google Scholar : PubMed/NCBI

21 

Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC and Ayanian JZ: Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol. 26:3860–3866. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O and Ash AS: Chemotherapy use among medicare beneficiaries at the end of life. Ann Intern Med. 138:639–643. 2003. View Article : Google Scholar : PubMed/NCBI

23 

Barnato AE, Herndon MB, Anthony DL, Gallagher PM, Skinner JS, Bynum JP and Fisher ES: Are regional variations in end-of-life care intensity explained by patient preferences? A Study of the US Medicare Population. Med Care. 45:386–393. 2007. View Article : Google Scholar : PubMed/NCBI

24 

Voogt E, van der Heide A, Rietjens JA, van Leeuwen AF, Visser AP, van der Rijt CC and van der Maas PJ: Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol. 23:2012–2019. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January 2018
Volume 8 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Rivoirard, R., Vallard, A., Boutet, C., Falk, A.T., Garin, C., Adjabi, A. ... Magné, N. (2018). A retrospective survey of the last 3 months of life in patients carrying glioblastoma: Clinical treatments and profiles. Molecular and Clinical Oncology, 8, 115-120. https://doi.org/10.3892/mco.2017.1479
MLA
Rivoirard, R., Vallard, A., Boutet, C., Falk, A. T., Garin, C., Adjabi, A., Hoarau, D., Forest, F., Fotso, M., Rancoule, C., Magné, N."A retrospective survey of the last 3 months of life in patients carrying glioblastoma: Clinical treatments and profiles". Molecular and Clinical Oncology 8.1 (2018): 115-120.
Chicago
Rivoirard, R., Vallard, A., Boutet, C., Falk, A. T., Garin, C., Adjabi, A., Hoarau, D., Forest, F., Fotso, M., Rancoule, C., Magné, N."A retrospective survey of the last 3 months of life in patients carrying glioblastoma: Clinical treatments and profiles". Molecular and Clinical Oncology 8, no. 1 (2018): 115-120. https://doi.org/10.3892/mco.2017.1479